Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that loliolide enhanced hair growth-related functions in 3D dermal papilla spheroids by activating AKT/β-catenin signaling pathways, with increased expression of related growth factors and genes.

The new compounds may be more effective and cheaper than current treatments for conditions like baldness.

This review assessed the safety of oral antiandrogen treatments for female androgenetic alopecia, finding spironolactone to be potentially safe even in high-risk populations, but indicated ongoing uncertainty regarding other medications, especially for patients with a history of gynecologic cancers.

This review discusses the role of androgens in male sexual differentiation and characteristics and reports no new clinical results; it emphasizes the androgen dependence of male pattern scalp hair loss.

This study discusses the physiopathogeny, clinical manifestations, and treatment objectives of androgenetic alopecia without reporting new clinical findings.

This review evaluates various topical treatments for androgenetic alopecia but does not provide new clinical findings, emphasizing the need for selecting therapies with limited systemic side effects.

This abstract does not provide any specific results or findings but describes male androgenic alopecia as a progressive and psychologically distressing hair-loss disorder involving hair follicle miniaturization.

In this animal study, AGO (agomelatine) effectively alleviated testosterone-induced benign prostatic hyperplasia in rats by reducing oxidative stress and inflammation, indicating its potential as a therapeutic option for managing BPH through specific signaling pathways.

In this study, osthenol was identified as a highly potent inhibitor of 5alpha-reductase type I in LNCaP cells, significantly outperforming finasteride.

This study introduced a new spectrofluorometric method using a synthesized organic fluorophore to effectively analyze darolutamide and thalidomide in pharmaceutical preparations and biofluids.

In this study, teicoplanin significantly improved hair regrowth and follicle size in mice with dihydrotestosterone-induced androgenetic alopecia, suggesting its potential as a treatment option for hair loss due to its ability to enhance cell proliferation and decrease androgen receptor protein levels.

This study explored the potential of stigmasterol as a treatment for androgenetic alopecia through various simulation techniques, finding promising interactions with key genes involved in hair loss, but further experimental validation is needed before clinical application.

This source reports that clascoterone cream has been approved in the U.S. for treating acne vulgaris in patients aged 12 and older, suggesting it works by competing with dihydrotestosterone at androgen receptors to mitigate acne's effects.

This article reviews the genetic and psychological aspects of androgenetic alopecia in men and women, reporting no new clinical findings while emphasizing the broad impact of this hair loss condition.

This study found that the Padina arborescens extract and its component MOGG may prevent hair loss by inhibiting 5α-reductase activity, promoting cell proliferation, opening the KATP channel, and increasing PGE2 production in laboratory settings.

This study demonstrated that derivatives of dehydroepiandrosterone (2a-b, 3a-f, and 4a-f) significantly reduced viable LNCaP prostate cancer cells, suggesting potential therapeutic use for metastatic prostate cancer, while finasteride did not alter cell viability.

This study reports that a new minoxidil and epigallocatechin gallate co-loaded ionic liquids system showed superior efficacy in promoting hair regrowth in a mouse model of androgenic alopecia by activating hair follicle stem cells and improving microenvironment conditions, compared to existing minoxidil products.

This review highlighted current treatments for androgenetic alopecia and proposed a management algorithm, noting additional therapies show effectiveness but lack inclusion in official guidelines due to the absence of randomized clinical trials.

This study investigated various synthesized 5-reductase inhibitors and found that compound 6 had the highest anti-androgenic activity and receptor affinity compared to finasteride, showing potential due to its improved efficacy and bioavailability for further research in treating lower urinary tract symptoms.

This abstract reviews the use and effects of various antiandrogens, finding clinical benefits in treating hyperandrogenism in women and improvements in urinary symptoms or cancer management in men, but it reports no new clinical results.

This review discusses androgenetic alopecia and existing treatments, reporting no new clinical results; the authors highlight promising prospects for androgen receptor degrader drugs among therapeutic options.

This review concluded that low-dose oral minoxidil is an effective and well-tolerated treatment for male androgenetic alopecia, with significant hair density improvements and manageable side effects.

In this study, researchers observed that RE-ORGA, a preparation from Korean herbs, may help alleviate androgenic alopecia by promoting human dermal papilla cell proliferation, reducing 5α-reductase enzyme levels, and displaying anti-inflammatory properties, suggesting potential regulation of androgen receptor sensitivity.

This study examines the pathogenetic mechanisms and morphological changes in androgenetic alopecia, highlighting the role of genetic and hormonal factors like dihydrotestosterone in hair follicle changes, which is crucial for developing effective diagnostics and treatments.

This study reports that a novel nanolipogel with moderate rigidity (NLG-2.5) enhances transdermal delivery of fucosterol, displaying superior permeability, targeting hair follicles, and promoting hair growth in androgenetic alopecia model mice by inhibiting inflammation and androgen pathways and promoting angiogenesis.

This study found that several new pregnane derivatives, especially steroids 16 and 19, demonstrated higher antiandrogenic activity on male hamster models than the commonly used finasteride.

In this study, human cell models of hair follicles showed that araliadiol, a plant-derived polyacetylene compound, promotes hair growth through the p38/PPAR-γ signaling pathway, suggesting its potential as a new drug candidate for alopecia treatment.

This article reviews research on androgen hormone profiles and the effects of androgens on hair follicles related to androgenetic alopecia, but reports no new experimental results.